This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Isaacs, C. E.
Right arrow Articles by Hillier, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Isaacs, C. E.
Right arrow Articles by Hillier, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2006, p. 1063-1066, Vol. 50, No. 3
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.3.1063-1066.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Inactivation of Herpes Simplex Virus Clinical Isolates by Using a Combination Microbicide

Charles E. Isaacs,1* Lisa Rohan,2 Weimin Xu,1 Jun Hua Jia,1 Timothy Mietzner,3 and Sharon Hillier4

Institute for Basic Research, 1050 Forest Hill Road, Staten Island, New York 10314,1 Laboratory No. 520, Magee Womens Research Institute School of Pharmacy, University of Pittsburgh, 204 Craft Avenue, Pittsburgh, Pennsylvania 15213,2 Department of Molecular Genetics and Biochemistry, BST 1240, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261,3 Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh/Magee Womens Hospital, 300 Halket Street, Pittsburgh, Pennsylvania 152134

Received 20 July 2005/ Returned for modification 1 September 2005/ Accepted 3 December 2005

A combination microbicide using the lipid-ether 1-0-octyl-sn-glycerol (OG) (3 mM) and peptide LSA5 (9 µM) synergistically inactivated six clinical isolates of herpes simplex virus type 2 (HSV-2) by 30- to 100-fold and five of six HSV-1 isolates by 10-fold more than the sum of OG and LSA5 used individually within 30 min. OG plus LSA5 inactivated all HSV clinical isolates by ≥1,000-fold in 10 to 40 min.

* Corresponding author. Mailing address: Institute for Basic Research, 1050 Forest Hill Road, Staten Island, NY 10314. Phone: (718) 494-5227. Fax: (718) 370-7205. E-mail: chisi{at}cunyvm.cuny.edu.

Antimicrobial Agents and Chemotherapy, March 2006, p. 1063-1066, Vol. 50, No. 3
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.3.1063-1066.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Skinner, M. C., Stamm, W. E., Lampe, M. L. (2009). Chlamydia trachomatis Laboratory Strains versus Recent Clinical Isolates: Implications for Routine Microbicide Testing. Antimicrob. Agents Chemother. 53: 1482-1489 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»